AbCellera Biologics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

AbCellera BiologicsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -28.2% zurückgegangen, während in der Branche Life Sciences die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 49.4% pro Jahr.

Wichtige Informationen

-28.2%

Wachstumsrate der Gewinne

-29.8%

EPS-Wachstumsrate

Life Sciences Wachstum der Industrie	26.8%
Wachstumsrate der Einnahmen	-49.4%
Eigenkapitalrendite	-13.0%
Netto-Marge	-410.5%
Nächste Ertragsaktualisierung	06 Aug 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie AbCellera Biologics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

DB:8QQ Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	36	-147	77
31 Dec 23	38	-146	75
30 Sep 23	50	-129	72
30 Jun 23	145	-74	71
31 Mar 23	181	-50	69
31 Dec 22	485	159	67
30 Sep 22	603	248	66
30 Jun 22	507	200	61
31 Mar 22	489	205	56
31 Dec 21	375	153	49
30 Sep 21	444	177	40
30 Jun 21	448	197	31
31 Mar 21	431	203	21
31 Dec 20	233	85	16
30 Sep 20	28	0	9
30 Jun 20	23	2	7
31 Mar 20	14	-3	5
31 Dec 19	12	-2	4
31 Dec 18	9	0	3

Qualität der Erträge: 8QQ ist derzeit unrentabel.

Wachsende Gewinnspanne: 8QQ ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 8QQ ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 28.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von 8QQ verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: 8QQ ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Life Sciences (-1.7%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: 8QQ hat eine negative Eigenkapitalrendite (-13%), da es derzeit unrentabel ist.

AbCellera Biologics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

AbCellera Biologics Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2023)

AbCellera Biologics Inc. to Report Q1, 2024 Results on May 07, 2024

AbCellera Biologics Inc. to Report Fiscal Year 2023 Results on Feb 20, 2024

Third quarter 2023 earnings released: US$0.099 loss per share (vs US$0.093 profit in 3Q 2022)

AbCellera Biologics Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

AbCellera Biologics Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2023)

AbCellera Biologics Inc., Annual General Meeting, Jun 13, 2024

AbCellera Biologics Inc. to Report Q1, 2024 Results on May 07, 2024

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera Biologics Inc. Announces Board Changes

AbCellera Biologics Inc. to Report Fiscal Year 2023 Results on Feb 20, 2024

Abcellera Biologics, Inc. Announces Reorganization

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Third quarter 2023 earnings released: US$0.099 loss per share (vs US$0.093 profit in 3Q 2022)

AbCellera Biologics Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.024 loss in 2Q 2022)

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing

New major risk - Share price stability

AbCellera Biologics Inc. to Report Q2, 2023 Results on Aug 03, 2023

DAMONA Pharmaceuticals Appoints John Reilly as Member of the Board of Directors

Chief Financial Officer recently bought €93k worth of stock

First quarter 2023 earnings released: US$0.14 loss per share (vs US$0.59 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$0.56 (vs US$0.56 in FY 2021)

AbCellera Biologics Inc. to Report Fiscal Year 2022 Results on Feb 21, 2023

CEO, President & Chairperson recently bought €810k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: US$0.093 (vs US$0.077 loss in 3Q 2021)

Investor sentiment improved over the past week

AbCellera Biologics Inc. to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

CEO, President & Chairperson recently bought €2.3m worth of stock

Investor sentiment improved over the past week

Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.009 loss in 2Q 2021)

AbCellera Biologics Inc. to Report Q2, 2022 Results on Aug 09, 2022

AbCellera Biologics Inc. Announces Departure of Neil Berkley as Chief Business Officer

CEO, President & Chairperson recently bought €494k worth of stock

Investor sentiment improved over the past week

CEO, President & Chairperson recently bought €453k worth of stock

CEO, President & Chairperson recently bought €8.7m worth of stock

First quarter 2022 earnings released: EPS: US$0.59 (vs US$0.43 in 1Q 2021)

Investor sentiment deteriorated over the past week

AbCellera Biologics Inc. to Report Q1, 2022 Results on May 10, 2022

Investor sentiment improved over the past week

Independent Non-Employee Director recently bought €163k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

AbCellera Biologics Inc. Announces Bebtelovimab Receive Emergency Use Authorization from the U.S. Food and Drug Administration

Investor sentiment improved over the past week

AbCellera Biologics Inc. to Report Q4, 2021 Results on Feb 24, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

President recently bought €2.6m worth of stock

Third quarter 2021 earnings released: US$0.077 loss per share (vs US$0.013 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

AbCellera Biologics Inc. (NasdaqGS:ABCL) acquired TetraGenetics, Inc.

Independent Non-Employee Director recently sold €4.3m worth of stock

Independent Non-Employee Director recently bought €88k worth of stock

Second quarter 2021 earnings released: US$0.009 loss per share (vs US$0.044 profit in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS US$0.43 (vs US$0.011 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$0.75 (vs US$0.015 loss in FY 2019)

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

AbCellera Announces That the European Medicines Agency's Committee for Medicinal Products for Human Use Has Issued A Positive Scientific Opinion for Bamlanivimab Alone and Bamlanivimab Administered Together with Etesevimab

AbCellera Appoints Ester Falconer as Chief Technology Officer

AbCellera-Discoveres Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

AbCellera Biologics Inc. to Report Q4, 2020 Results on Mar 29, 2021

Abcellera Biologics Inc. Announces Key Details from the Blaze-2 Study

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn